论文部分内容阅读
目的:探讨血液透析(HD)联合尿毒清颗粒(UCG)口服对终末期肾病患者蛋白结合型毒素水平的影响。方法:选取2018年1月至2019年5月在南京医科大学附属江宁医院血液净化中心行HD的患者80例，采用随机数字表法分为HD联合UCG组、HD组各40例。HD组行常规HD治疗；HD联合UCG组在常规HD基础上口服UCG。随访观察24周，测定并比较两组患者治疗前后硫酸对甲酚(PCS)、硫酸吲哚酚(IS)水平。结果:治疗前，两组PCS、IS差异均无统计学意义(均n P>0.05)。治疗8周、16周、24周，HD联合UCG组PCS分别为(19.58±13.25)mg/L、(18.44±11.78)mg/L、(18.03±11.94)mg/L，IS分别为(24.28±15.36)mg/L、(23.54±15.07)mg/L、(23.69±14.83)mg/L，均低于HD组[PCS：(25.64±16.73)mg/L、(23.26±14.15)mg/L、(24.86±15.31)mg/L，IS：(36.72±19.48)mg/L、(33.59±17.38)mg/L、(33.92±16.61)mg/L]，差异均有统计学意义(n t＝2.057、2.103、2.318，2.615、2.413、2.701，均n P0.05). After treatment for 8, 16, 24 weeks, the concentrations of PCS in the HD+ UCG group were (19.58±13.25)mg/L, (18.44±11.78)mg/L, (18.03±11.94)mg/L, respectively, and the IS levels in the HD+ UCG group were (24.28±15.36)mg/L, (23.54±15.07)mg/L, (23.69±14.83)mg/L, respectively, which were all lower than those in the HD group[PCS: (25.64±16.73)mg/L, (23.26±14.15)mg/L, (24.86±15.31)mg/L; IS: (36.72±19.48)mg/L, (33.59±17.38)mg/L, (33.92±16.61)mg/L], the differences were statistically significant(n t=2.057, 2.103, 2.318, 2.615, 2.413, 2.701, all n P<0.05). And no serious adverse reactions occurred in all patients.n Conclusion:Administration of UCG orally can decrease the concentration of serum protein-bound uremic toxins such as PCS and IS continuously and effectively in patients with ESRD.